A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy

Trial Profile

A Double Blind, Placebo Controlled, Pivotal Phase III Study Evaluating Xilonix in Symptomatic Colorectal Cancer Patients Refractory To Standard Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs MABp1 (Primary)
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors XBiotech
  • Most Recent Events

    • 13 Oct 2017 This study has been completed in Poland as per European Clinical Trials Database.
    • 10 Oct 2017 This trial has been completed in Hungary (End Date:2017-07-07).
    • 26 Jun 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top